CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 54 filers reported holding CARDIFF ONCOLOGY INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $531,932 | -85.4% | 239,609 | -64.9% | 0.00% | -100.0% |
| Q1 2024 | $3,648,817 | +4992.8% | 683,299 | +1302.0% | 0.00% | – |
| Q2 2023 | $71,646 | +41554.7% | 48,739 | -53.1% | 0.00% | – |
| Q1 2023 | $172 | -12.7% | 103,942 | -26.2% | 0.00% | – |
| Q4 2022 | $197 | -99.9% | 140,767 | -29.5% | 0.00% | – |
| Q3 2022 | $308,000 | -64.4% | 199,787 | -49.2% | 0.00% | -100.0% |
| Q2 2022 | $866,000 | +22.5% | 393,603 | +38.1% | 0.00% | – |
| Q1 2022 | $707,000 | -71.9% | 284,994 | -32.0% | 0.00% | -100.0% |
| Q4 2021 | $2,517,000 | +196.5% | 418,880 | +228.5% | 0.00% | 0.0% |
| Q3 2021 | $849,000 | -71.6% | 127,498 | -60.5% | 0.00% | -50.0% |
| Q1 2021 | $2,991,000 | +419.3% | 322,962 | +908.0% | 0.00% | – |
| Q4 2020 | $576,000 | -56.8% | 32,041 | -65.9% | 0.00% | -100.0% |
| Q3 2020 | $1,333,000 | – | 93,953 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 120,600 | $265,000 | 0.37% |
| Artal Group S.A. | 750,000 | $1,650,000 | 0.09% |
| XTX Topco Ltd | 55,081 | $121,000 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 117,295 | $258,000 | 0.04% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 23,800 | $52,000 | 0.03% |
| Atom Investors LP | 33,798 | $74,000 | 0.03% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 296,507 | $652,000 | 0.03% |
| Laurion Capital Management LP | 722,100 | $1,589,000 | 0.02% |
| MYDA Advisors LLC | 30,000 | $66,000 | 0.02% |
| Ergoteles LLC | 184,000 | $405,000 | 0.01% |